

## Summary table of consultee and commentator comments on review proposal

| Respondent                                    | Response to proposal  | Details   | Comment from Technology Appraisal  |
|---|---|---|--|
| Action Against Allergy                        | No comment  |   |  |
| Astellas Pharma Inc                           | No objections (response provided as commercial in confidence and therefore not publicly released) |   |  |
| Board of Community Health Councils in Wales   | No comment  |   |  |
| British Association of Dermatologists         | No objection  |   |  |
| British National Formulary                    | No comment  |   |  |
| Department of Health                          | No comment  |   |  |
| Dowelhurst Ltd                                | Agree   |   |  |
| GlaxoSmithKline                               | No objection  |   |  |
| National Eczema Society                       | Agree   |   |  |
| National Public Health Service for Wales      | No comment  |   |  |
| NHS Quality Improvement Scotland              | No comment  |   |  |
| Novartis Pharmaceuticals                      | Agree   |   |  |
| Primary Care Dermatology Society              | Agree   |   |  |
| Royal College of Nursing                      | No comment  |   |  |
| Royal College of Paediatrics and Child Health | Agree   |   |  |
| Royal College of Physicians                   | No objection  |   |  |
| Sandoz Limited                                | No objection  |   |  |
| Westminster PCT                               | Agree   |   |  |
| Cochrane Skin Group                           |   | The consultee sent a copy of a new Cochrane Review: Topical pimecrolimus for eczema | The Cochrane review does not affect this decision and the information will be included in any future review of this appraisal. |

### No response received from:

|  |  |
|--|--|
| <u>Patient/carer groups</u> <ul style="list-style-type: none"> <li>Action for Sick Children</li> </ul> | <u>Comparator manufacturers</u> <ul style="list-style-type: none"> <li>Co-Pharma (hydrocortisone)</li> </ul> |
|--|--|

National Institute for Health and Clinical Excellence

Summary table of consultees and commentators comments for existing guidance no. 82; on the use of tacrolimus and pimecrolimus for the treatment of atopic dermatitis

Issue date: December 2007

Page 1 of 2

If you have any queries regarding this correspondence please contact Andrew Gyton by email: [andrew.gyton@nice.org.uk](mailto:andrew.gyton@nice.org.uk) or telephone: 020 7067 5886

|  |  |
|--|--|
| <ul style="list-style-type: none"> <li>• Age Concern England</li> <li>• Allergy UK</li> <li>• Black Health Agency</li> <li>• Changing Faces</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Help the Aged</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• Skin Care Campaign</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• WellChild</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Services to the Elderly</li> <li>• British Dermatological Nursing Group</li> <li>• British Skin Foundation</li> <li>• Community Practitioners and Health Visitors Association</li> <li>• National Association of Primary Care</li> <li>• Royal College of General Practitioners</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Warrington PCT</li> <li>• Welsh Assembly Government</li> </ul> <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• Scottish Medicines Consortium</li> </ul> | <ul style="list-style-type: none"> <li>• Derma UK (fluocinolone acetonide, fluocinonide)</li> <li>• Dermal (hydrocortisone, betamethasone valerate)</li> <li>• Diomed Developments Ltd (hydrocortisone)</li> <li>• Galpharm Healthcare (hydrocortisone)</li> <li>• Meadow Laboratories (fluocortolone, diflucortolone valerate)</li> <li>• Pliva Pharma (aclometasone dipropionate)</li> <li>• Reckitt Benckiser Healthcare UK (hydrocortisone)</li> <li>• Roussel Laboratories (hydrocortisone)</li> <li>• Teva Pharmaceutical Industries Ltd (hydrocortisone, hydrocortisone generic)</li> <li>• Scottish Medicines Consortium</li> <li>• Actavis (hydrocortisone)</li> <li>• Astellas (hydrocortisone, hydrocortisone butyrate)</li> <li>• BCM Specials (hydrocortisone)</li> <li>• Bell Sons &amp; Co. (hydrocortisone)</li> <li>• Biorex Laboratories (hydrocortisone)</li> <li>• Celltech (betamethasone valerate)</li> <li>• Thornton &amp; Ross (hydrocortisone)</li> <li>• Typharm (fludroxycortide)</li> <li>• UCB Pharma (betamethasone valerate)</li> <li>• Waymade (hydrocortisone)</li> <li>• Wockhardt UK Ltd (hydrocortisone generic)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Skin Research Centre</li> <li>• Skin Treatment &amp; Research Trust</li> <li>• The British Epidermo-Epidemiology Society</li> </ul> <p><u>Assessment team</u></p> <ul style="list-style-type: none"> <li>• National Coordinating Centre for Health Technology Assessment</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Women and Children</li> </ul> |
|--|--|

National Institute for Health and Clinical Excellence

Summary table of consultees and commentators comments for existing guidance no. 82; on the use of tacrolimus and pimecrolimus for the treatment of atopic dermatitis

Issue date: December 2007